cIAP1 Ligand-Linker Conjugates 4 are specialized chemical tools designed for use in the development of PROTACs (Proteolysis Targeting Chimeras). As a member of the E3 Ligase Ligand-Linker Conjugate category, these conjugates feature a high-affinity ligand for the cellular inhibitor of apoptosis protein 1 (cIAP1) E3 ubiquitin ligase, connected to a flexible linker that enables attachment to a desired target ligand. In PROTAC technology, cIAP1 Ligand-Linker Conjugates 4 facilitate targeted protein degradation by recruiting the cIAP1 E3 ligase to a specific protein of interest, thereby promoting its ubiquitination and subsequent proteasomal degradation. This approach is widely employed in drug discovery research, particularly for validating novel therapeutic targets and developing next-generation therapeutics against challenging proteins. Trusted by medicinal chemists and researchers, cIAP1 Ligand-Linker Conjugates 4 offer high purity and optimal linker designs to support efficient and selective PROTAC assembly.
Quality Assurance
Worldwide Delivery
24/7 Customer Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C55H67N5O11
Molecular Weight
974.15
* For research and manufacturing use only. Not for human or clinical use.
Size
Price
Stock
Quantity
--
$--
In stock
Looking for different specifications? Click to request a custom quote!
cIAP1 Ligand-Linker Conjugates 4 are sophisticated chemical tools designed for targeted protein degradation in the field of drug discovery and chemical biology. Built upon the concept of PROTACs (Proteolysis Targeting Chimeras), these conjugates employ a specific ligand for cIAP1 (cellular inhibitor of apoptosis protein 1), an E3 ubiquitin ligase involved in regulating apoptosis and cellular signaling pathways. The linker region of the molecule enables connection to other functional units, such as target protein binders, supporting the modular assembly of next-generation degraders.
Mechanism
The mechanism of action of cIAP1 Ligand-Linker Conjugates 4 centers on their ability to recruit the cIAP1 E3 ubiquitin ligase to a protein of interest (POI) when incorporated into bifunctional degrader molecules, such as PROTACs. By chemically linking the cIAP1 ligand to a separate ligand that binds a target protein, the conjugate mediates spatial proximity between cIAP1 and the POI. This inducible proximity enables cIAP1 to ubiquitinate the target protein, marking it for recognition and degradation by the cell's proteasome system, thereby selectively reducing disease-related or unwanted protein levels in cells.
Applications
cIAP1 Ligand-Linker Conjugates 4 are widely utilized in the development of PROTACs and related heterobifunctional degraders. These conjugates are essential for: 1) Drug discovery programs aimed at identifying novel therapeutics for cancer, inflammation, and neurodegenerative disorders. 2) Chemical biology studies exploring the functional consequences of rapid protein depletion in cells and animal models. 3) The creation of custom-designed PROTACs for degrading previously 'undruggable' targets by leveraging cIAP1 as the recruiting E3 ligase. With their established utility and versatility, cIAP1 Ligand-Linker Conjugates 4 empower researchers to break new ground in targeted protein degradation and precision medicine research.
• Designed for selective targeting of cIAP1, enabling precise protein degradation in PROTAC applications
• Versatile linker facilitates efficient conjugation with various warheads, streamlining custom PROTAC development
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Cat No.: BP-100089
